HK1032740A1 - A combination of a selective 5-ht1a antagonist and a selective h5-ht1b antagonist or partial agonist - Google Patents

A combination of a selective 5-ht1a antagonist and a selective h5-ht1b antagonist or partial agonist

Info

Publication number
HK1032740A1
HK1032740A1 HK00107467A HK00107467A HK1032740A1 HK 1032740 A1 HK1032740 A1 HK 1032740A1 HK 00107467 A HK00107467 A HK 00107467A HK 00107467 A HK00107467 A HK 00107467A HK 1032740 A1 HK1032740 A1 HK 1032740A1
Authority
HK
Hong Kong
Prior art keywords
selective
antagonist
combination
partial agonist
ht1b
Prior art date
Application number
HK00107467A
Other languages
English (en)
Inventor
Stefan Berg
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1032740A1 publication Critical patent/HK1032740A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK00107467A 1997-09-18 2000-11-22 A combination of a selective 5-ht1a antagonist and a selective h5-ht1b antagonist or partial agonist HK1032740A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703374A SE9703374D0 (sv) 1997-09-18 1997-09-18 A new combination
PCT/SE1998/001600 WO1999013876A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Publications (1)

Publication Number Publication Date
HK1032740A1 true HK1032740A1 (en) 2001-08-03

Family

ID=20408294

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00107467A HK1032740A1 (en) 1997-09-18 2000-11-22 A combination of a selective 5-ht1a antagonist and a selective h5-ht1b antagonist or partial agonist

Country Status (30)

Country Link
US (1) US6159972A (sv)
EP (1) EP1021183B1 (sv)
JP (1) JP2001516717A (sv)
KR (1) KR20010024075A (sv)
CN (1) CN1182847C (sv)
AR (1) AR015447A1 (sv)
AT (1) ATE261728T1 (sv)
AU (1) AU752718B2 (sv)
BR (1) BR9812234A (sv)
CA (1) CA2302383A1 (sv)
DE (1) DE69822490T2 (sv)
DK (1) DK1021183T3 (sv)
EE (1) EE04142B1 (sv)
ES (1) ES2216307T3 (sv)
HK (1) HK1032740A1 (sv)
HU (1) HUP0100401A3 (sv)
IL (1) IL134774A0 (sv)
IS (1) IS5408A (sv)
MY (1) MY116281A (sv)
NO (1) NO20001398L (sv)
NZ (1) NZ503174A (sv)
PL (1) PL339370A1 (sv)
PT (1) PT1021183E (sv)
RU (1) RU2215528C2 (sv)
SE (1) SE9703374D0 (sv)
SK (1) SK2842000A3 (sv)
TR (1) TR200000734T2 (sv)
TW (1) TW568786B (sv)
WO (1) WO1999013876A1 (sv)
ZA (1) ZA987810B (sv)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO2002066454A1 (en) * 2001-02-21 2002-08-29 Sankyo Company, Limited Chromene derivatives
WO2003007956A1 (en) * 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
USD969017S1 (en) 2021-06-28 2022-11-08 Koninklijke Asscher Diamant Maatschappij B.V. Rose marquise diamond article

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
FI961247A0 (fi) * 1996-03-18 1996-03-18 Finnish Peroxides Ab Oy Foerfarande foer loesning av uppsvaellningsproblem i en avfalls vattenreningsanordning foer kontroll av traodartiga bakterier
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
TR200000734T2 (tr) 2000-11-21
SE9703374D0 (sv) 1997-09-18
MY116281A (en) 2003-12-31
DE69822490D1 (de) 2004-04-22
AR015447A1 (es) 2001-05-02
BR9812234A (pt) 2000-07-18
ES2216307T3 (es) 2004-10-16
HUP0100401A3 (en) 2003-01-28
EP1021183A1 (en) 2000-07-26
NO20001398D0 (no) 2000-03-17
PT1021183E (pt) 2004-07-30
CN1182847C (zh) 2005-01-05
AU752718B2 (en) 2002-09-26
EE04142B1 (et) 2003-10-15
TW568786B (en) 2004-01-01
WO1999013876A1 (en) 1999-03-25
IL134774A0 (en) 2001-04-30
JP2001516717A (ja) 2001-10-02
EE200000143A (et) 2001-02-15
ATE261728T1 (de) 2004-04-15
EP1021183B1 (en) 2004-03-17
PL339370A1 (en) 2000-12-18
IS5408A (is) 2000-03-15
NO20001398L (no) 2000-04-04
NZ503174A (en) 2002-03-01
DE69822490T2 (de) 2005-03-03
RU2215528C2 (ru) 2003-11-10
CN1279609A (zh) 2001-01-10
ZA987810B (en) 1999-02-18
HUP0100401A2 (hu) 2002-01-28
US6159972A (en) 2000-12-12
AU9192998A (en) 1999-04-05
SK2842000A3 (en) 2000-09-12
KR20010024075A (ko) 2001-03-26
DK1021183T3 (da) 2004-07-05
CA2302383A1 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
PL337781A1 (en) Antagonists and reverse antagonists of glucogene
HK1124339A1 (en) 20-keto-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal activity 20--11-
HUP0101948A3 (en) Il-2 selective agonists and antagonists
HU9900592D0 (en) Compound and its use
EP0934305A4 (en) INTEGRINE ANTAGONISTS
EP0946164A4 (en) INTEGRIN ANTAGONISTS
IL134776A0 (en) A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST
ZA987804B (en) A combination of a monoamine oxidase inhibitor and a H5-HT1b antagonists or agonist
EP1056455A4 (en) EPIMORPHIN COMPOUND AND USE OF THE SAME
GB0012203D0 (en) Reamer and method of using the same
SG77642A1 (en) Point of use dilution tool and method
GB9704349D0 (en) Levobupivacaine and its use
HK1032740A1 (en) A combination of a selective 5-ht1a antagonist and a selective h5-ht1b antagonist or partial agonist
GB9820014D0 (en) Receptor antagonists and uses thereof
HUP0104723A3 (en) New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use
GB9701374D0 (en) Purinergic agonists and antagonists
GB9617507D0 (en) Chemically modified elastomeres and blends thereof
SI1021183T1 (en) A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST
GB9704370D0 (en) Levobupivacaine and its use
PL56866Y1 (en) Boring and facing head
GB9722023D0 (en) Levobupivacaine and its use
ZA989647B (en) Drilling and cementing through shallow waterflows
GB9716815D0 (en) Hole cutting and forming apparatus
GB9810427D0 (en) Levobupivacaine and its use
GB9816014D0 (en) Piperidinecarboxamides and their use

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080909